

## Onexton - (3.75%; EQ 1.2% BASE; Gel, Topical)

<b>Generic Name</b>	Clindamycin Phosphate and Benzoyl Peroxide	<b>Innovator</b>	Dow Pharma
<b>Dosage</b>	3.75%; EQ 1.2% BASE; Gel, Topical	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	Less Than 5
<b>Indication</b>	once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.